Background. Pregnant women were at increased risk for serious outcomes of 2009 pandemic influenza A virus subtype H1N1 (influenza A[H1N1]pdm09) infection, but little is known about the overall impact of the pandemic on neonatal and maternal outcomes.
Methods. We identified live births that occurred from 1 July 2008 through 31 May 2010 in 5 Kaiser Permanente regions. Pregnant women were considered to have influenza if they had a positive result of a laboratory test for influenza virus or if they received a diagnosis of influenza during a period in which seasonal influenza virus or A(H1N1)pdm09 was the predominant circulating virus.
Results. There were 111 158 births from 109 015 pregnancies involving 107 889 mothers; 368 pregnant women (0.3%) received a diagnosis of influenza due to seasonal virus, and 959 (0.9%) received a diagnosis of influenza due to A(H1N1)pdm09; 107 688 did not receive an influenza diagnosis. Pregnant women with influenza due to A(H1N1)pdm09 were more likely than women with seasonal influenza infection to be hospitalized within 30 days of the diagnosis (27% vs 12%; odds ratio [OR], 2.84 [95% confidence interval {CI}, 2.01-4.02]). Pregnant women with A(H1N1)pdm09 who started antiviral treatment ≥2 days after the diagnosis were significantly more likely to be hospitalized than those who started antiviral treatment <2 days after diagnosis (OR, 3.43 [95% CI, 1.55-7.56]). Mothers with seasonal influenza virus infection had an increased risk for having a small-forgestational-age infant (OR, 1.59 [95% CI, 1.15-2.20]).
Conclusions. In this large, geographically diverse population, A(H1N1)pdm09 infection increased the risk for hospitalization during pregnancy. Late initiation of antiviral treatment was also associated with an increased risk for hospitalization.
Influenza disproportionately affects pregnant women. Healthy pregnant women exposed to influenza are at an increased risk for pregnancy complications, severe illness, hospitalization, and death [1] [2] [3] . During past influenza pandemics, mortality among pregnant women considerably exceeded that of the general population [1] , and pregnant women infected with influenza virus were at increased risk of adverse outcomes, including preterm birth [2] . Studies of pregnant women infected with 2009 pandemic influenza A virus subtype H1N1 (A[H1N1]pdm09) have also demonstrated greater morbidity and mortality than nonpregnant women infected with A(H1N1)pdm09 [1, 3, 4] , and these differences are likely greater than those between pregnant and nonpregnant women during seasonal epidemics [3, 5] .
In June 2009, the World Health Organization (WHO) designated A(H1N1)pdm09 infection as a global pandemic [6, 7] . Compared with seasonal influenza virus infection, A(H1N1)pdm09 infection disproportionately affected younger people and pregnant women [5] , and >10% of early A(H1N1)pdm09-related deaths in the United States occurred among pregnant women [3] . Hospitalization rates among pregnant women with confirmed A(H1N1)pdm09 infection were 4 times those in the general population [2, 4] .
There are limited population-based data concerning the full impact of A(H1N1)pdm09 infection on pregnant women and their infants [8] , and it remains unclear what differences exist between A(H1N1)pdm09 and seasonal influenza virus in relation to pregnancy and birth outcomes [5] . In this study, we assessed the impact of A(H1N1)pdm09 infection during pregnancy on a wide range of maternal and neonatal outcomes, compared with uninfected pregnant women and women infected with seasonal influenza virus. We examined all pregnancies resulting in a live birth between July 2008 and May 2010 in a geographically and racially diverse Kaiser Permanente (KP) population.
METHODS

Study Design and Data Collection
We identified all live births that occurred between 1 July 2008 and 31 May 2010 within 5 KP regions (Northern and Southern California, Colorado, Georgia, and Mid-Atlantic States) and used KP electronic medical records and administrative databases to link information about mothers and their infants. The KP sites have a population of approximately 6.5 million members in the California regions, 500 000 in the Mid-Atlantic region, 475 000 in the Colorado region, and 240 000 in the Georgia region. These populations are racially and ethnically diverse, with white race reported by approximately 67% of members in the Northern California region (followed by Asian American, for 13%), by 40% in the Southern California region (followed by Hispanic, for 38%), by 46% in the MidAtlantic region (followed by African American, for 45%), by 75% in the Colorado region (followed by Hispanic, for 15%), and by 63% in the Georgia region (followed by African American, for 33%), and are representative of the overall metropolitan areas in which they are situated.
The study period encompassed many pregnancies occurring during the period of A(H1N1)pdm09 circulation, as well as those from the prior influenza season. To capture underlying maternal health status, diagnoses were identified for up to 1 year prior to delivery. To determine maternal and infant outcomes, we extracted information for up to 1 month after delivery. To be included in the final cohort, a mother had to be enrolled for her entire pregnancy, with enrollment gaps of up to 45 days allowed. This study was funded by the KP Center for Effectiveness and Safety Research and received approval from each region's institutional review board.
Influenza Exposure
The following 3 groups were created to assess maternal and neonatal outcomes associated with seasonal influenza virus and A(H1N1)pdm09 infection during pregnancy: women with medically attended A(H1N1)pdm09 infection, women with medically attended seasonal influenza virus infection, and women who did not receive an influenza diagnosis. Seasonal influenza virus or A(H1N1)pdm09 infection was defined by having a reverse-transcription polymerase chain reaction (RT-PCR) test positive for influenza virus or by having a medical visit during pregnancy in which an influenza diagnosis (defined as International Classification of Diseases, Ninth Revision-Clinical Modification (ICD-9-CM) codes 487.0, 487.1, 487.8, 488.0, 488.1, and 488.12) was received during the period of predominant circulation of either seasonal influenza virus or A(H1N1)pdm09. When multiple diagnoses or positive results of laboratory tests were recorded during pregnancy, the earliest laboratory test result or diagnosis code date was designated as the infection onset date. To identify periods during which seasonal influenza virus and A(H1N1)pdm09 were the predominant circulating viruses, we obtained influenza virus surveillance data from the Centers for Disease Control and Prevention.
The seasonal influenza virus circulation period was defined as the weeks during which the percentage of specimens that tested positive for influenza virus was >5%. The onset date for the A(H1N1)pdm09 circulation period was defined as the collection date of the specimen associated with the first positive laboratory test result, and the end date was defined as the first week when the proportion of laboratory tests positive for A (H1N1)pdm09 was <5%.
Pregnancy Outcomes
Neonatal outcomes examined included preterm birth (<37 weeks gestation), birth weight, head circumference, birth length, APGAR scores, intrauterine hypoxia and birth asphyxia, perinatal jaundice, respiratory conditions, perinatal infections, and respiratory distress syndrome. Low birth weight (LBW) was defined as a birth weight of <2500 g, and small for gestational age (SGA) was defined as a birth weight of <10th percentile for gestational age and sex. The 10th percentile cutoffs were obtained from national birth weight percentiles [9] . Head circumference and birth length were dichotomized using a cutoff of <10th percentile, by sex, as estimated from our birth cohort.
Pregnancy complications examined included polyhydramnios, oligohydramnios, amniotes, antepartum hemorrhage, abruptio placentae, placenta previa, hypertension (including eclampsia and preeclampsia), and fetal abnormalities or placental problems that could affect the management of the mother (eg, central nervous system malformation in fetus, chromosomal abnormality in fetus, and suspected damage to fetus from viral disease; ICD-9-CM codes are available in the Supplementary Materials). Antepartum complications were classified as puerperal infections, venous complications, fever, pulmonary embolism, and other antepartum complications. For these outcomes, we wanted to observe general associations with A(H1N1)pdm09 and seasonal influenza virus without assuming causality, and therefore the timing of the diagnosis for these conditions was not considered.
To assess the risk of influenza among pregnant mothers with medical conditions that, on the basis of previous literature [4, [10] [11] [12] [13] , increase the risk of adverse influenza-related outcomes, we identified women with diagnoses of asthma, diabetes, anemia, cardiovascular diseases, immune suppression, neurological diseases, or obesity. These conditions were identified from 90 days prior through 90 days after the last menstrual period, except for gestational diabetes, which was diagnosed from the last menstrual period through birth. For these analyses, the mother had to be continuously enrolled from the 90 days prior to pregnancy through delivery; therefore, a subset (approximately 90%) of the main cohort was used. A list of ICD-9-CM codes is shown in the Supplementary Materials.
Hospitalization
We classified "hospitalization" as any inpatient stay, including stays of <1 and >1 day. To examine the risk of hospitalization after influenza virus infection, we identified hospitalizations within 30 days of influenza diagnosis. In some cases, the hospitalization and influenza diagnosis occurred simultaneously (ie, for a woman who first received an influenza diagnosis at hospital admission, the hospitalization was counted as occurring within 30 days of the influenza diagnosis).
Antiviral Dispensing
Antiviral dispensing was determined using KP electronic pharmacy files, which include data on outpatient dispensing only. Specific antivirals examined included amantadine, oseltamivir, and zanamivir. To examine the effectiveness of antiviral therapy among mothers with A(H1N1)pdm09 infection, we compared early (ie, within 2 days of diagnosis) with late (ie, 3-7 days after diagnosis) dispensing of antivirals.
Statistical Analyses
Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using generalized estimating equations to account for multiple pregnancies or deliveries. In all cases, ORs for the seasonal influenza virus and A(H1N1)pdm09 groups were calculated using the group of women who did not receive a diagnosis of influenza as the reference group. On the basis of a priori considerations of potential confounders, the models examining neonatal outcomes were adjusted for gestational age (except when examining SGA and preterm birth), maternal age, race and smoking status, plurality, and study region. The models examining maternal outcomes were adjusted for the same group of covariates, excluding gestational age.
RESULTS
A(H1N1)pdm09 Circulation Periods
Laboratory tests positive for A(H1N1)pdm09 first appeared during the week of 26 April 2009, when 3.4%, 5.5%, and 7.6% of tests in the South Atlantic, Mountain, and Pacific census regions, respectively, were positive, and peaked shortly thereafter. The end dates, in which the percentage of specimens that tested positive for influenza virus was <5%, were 3 April 2010, 12 December 2009, and 2 January 2010 for the South Atlantic, Mountain, and Pacific census regions, respectively. An additional 14-day grace period was applied to these dates.
Pregnancy and Birth Cohorts
There were 111 191 births from 109 047 pregnancies for 107 918 mothers who were enrolled for their entire pregnancy ( Figure 1 ). Of these pregnancies, 32 (33 births) were excluded from analysis because of a laboratory test positive for influenza B virus during the period of A(H1N1)pdm09 circulation (for 3 pregnancies), the onset date fell after the A(H1N1)pdm09 circulation period (for 15), or the onset date fell after the period of seasonal influenza virus circulation (for 14). Therefore, there were a total of 111 158 births, 109 015 pregnancies, and 107 889 mothers in the final analyses.
A total of 368 pregnant women (0.3%) received a diagnosis of influenza during a period when seasonal influenza viruses predominated, 959 (0.9%) received a diagnosis during period when A(H1N1)pdm09 predominated, and 107 688 (98.8%) received no diagnosis (Figure 1 ). Most pregnancies within the seasonal influenza virus (82.6%) and A(H1N1)pdm09 exposure groups (71.2%) were classified by diagnosis code, 10.6% and 11.3% of the pregnancies with exposure to seasonal influenza virus and A(H1N1)pdm09 were classified by a positive result of a laboratory test, and 6.8% and 17.4% were classified via diagnosis code and positive test result (Figure 1) .
Compared with pregnant women who did not receive a diagnosis of influenza, women infected with either seasonal influenza virus or A(H1N1)pdm09 were less likely to be white and more likely to be younger ( predominantly ages 20-29 years) ( Table 1) . Diagnoses of seasonal influenza virus infection were most common during the first trimester, whereas A (H1N1)pdm09 infection was diagnosed mostly during the second and third trimesters.
Neonatal Outcomes
The prevalences of preterm birth and LBW were slightly but not significantly higher among infants born to women who received a diagnosis of A(H1N1)pdm09 infection during pregnancy, compared with those delivered by women who did not ( 
Maternal Outcomes
A higher risk of fetal abnormalities affecting maternal management was seen with both seasonal influenza virus infection and A(H1N1)pdm09 infection (Table 3 ). In addition, women with a diagnosis of A(H1N1)pdm09 infection had a higher risk of fetal or placental problems, antepartum hemorrhage, and antepartum complications.
High-Risk Pregnancy Conditions
Women with a diagnosis of A(H1N1)pdm09 infection during pregnancy were more likely than mothers without an influenza diagnosis and mothers with a seasonal influenza virus infection diagnosis to be obese (29.8% vs 22.0% and 22.7%, respectively), to have asthma (8.1% vs 3.9% and 6.1%, respectively), and to have an underlying neurological comorbidity (3.6% vs 1.7% and 0.9%, respectively). Anemia was more common among mothers who received a diagnosis of either seasonal influenza virus or A(H1N1)pdm09 infection, compared with the reference group (Table 4) . Table 5 shows the major birth outcomes stratified by maternal obesity, asthma, and any comorbidity. 
Hospitalization
Mothers with a diagnosis of either seasonal influenza virus or A(H1N1)pdm09 infection were more likely to be hospitalized during pregnancy than the reference group of mothers. Of the 109 015 pregnant women in the reference group, 26.7% (28 771 of 109 015) had at least 1 inpatient stay (of any length) during pregnancy, compared with 38.6% of mothers (142 of 368) with a diagnosis of seasonal influenza virus infection and 44.6% of women (428 of 959) with a diagnosis of A(H1N1) pdm09 infection. Of the 959 pregnant women with a diagnosis of A(H1N1)pdm09 infection, 16 (1.7%) were hospitalized within 30 days with pneumonia, compared with only 1 mother with seasonal influenza virus infection; although this difference appears to be large, it did not reach statistical significance (OR, 6.23 [95% CI, .82-47.12]). When only considering inpatient stays of >1 day, 7.6% of women in the reference group (8143 of 109 015) were hospitalized during pregnancy, compared with 13.3% of mothers (49 of 368) with a diagnosis of seasonal influenza virus infection and 22.9% of mothers (220 of 959) with a diagnosis of A(H1N1)pdm09 infection.
In total, 262 A(H1N1)pdm09-infected pregnant women (27.3%) were hospitalized for any reason within 30 days of diagnosis, compared with 43 women (11.7%) with seasonal influenza virus infection (OR, 2.84 [95% CI, 2.01-4.02]). However, this result includes women who were hospitalized on the same day that they received their diagnosis. Therefore, we stratified the results by "hospitalized on the same day as diagnosis" and "hospitalized 1-30 days after diagnosis." There were 192 women (20.0%) with A(H1N1)pdm09 infection and 30 (8.2%) with seasonal influenza virus infection who were hospitalized on the same day as they received their diagnosis (OR, 2.82 [95% CI, 1.88-4.23]). There were 70 women (7.3%) with A(H1N1)pdm09 infection and 13 (3.5%) with seasonal influenza virus infection who were hospitalized 1-30 days after diagnosis (OR, 2.15 [95% CI, 1.17-3.93]). These analyses were repeated after excluding women who had a discharge on the same day as admission. Then, 146 A(H1N1)pdm09-infected pregnant women (15.2%) were hospitalized for any reason within 30 days of their diagnosis, compared with 15 women (4.1%) with seasonal influenza virus infection (OR, 4.22 [95% CI, 2.45-7.29]). Of these, 112 (11.7%) with A(H1N1)pdm09 infection and 9 (2.4%) with seasonal influenza virus infection were hospitalized on the same day as they received their diagnosis (OR, 5.27 [95% CI, 2.64, 10.51]), whereas 34 (3.6%) with A(H1N1)pdm09 infection and 6 (1.6%) with seasonal influenza virus infection were hospitalized 1-30 days after diagnosis (OR, 2.21 [95% CI, .92-5.32]).
Antiviral Use
There were 1395 antiviral dispensings to 1387 pregnant women, with oseltamivir accounting for 98% of dispensings. Of these women, 759 (0.7% of the total in the reference group) did not receive a diagnosis of influenza, 11 (3% of the total with seasonal influenza virus infection) received a diagnosis of seasonal influenza virus infection, and 617 (64% of the total with A(H1N1)pdm09 infection) received a diagnosis of A(H1N1)pdm09 infection. All dispensings to mothers with seasonal influenza virus infection occurred during trimesters 1 and 2 and within 5 days of the diagnosis date, whereas among mothers with A(H1N1)pdm09 infection, most dispensings occurred in trimesters 2 (40%) and 3 (50%). All models adjusted for gestational age, mother's age at delivery, plurality, race, study region, and smoking status, except for small for gestational age and preterm birth models, which did not adjust for gestational age. a The reference category is "No influenza."
b Confidence intervals (CIs) were calculated using generalized estimating equations to account for multiple pregnancies or deliveries.
c Data were missing for 2380 outcomes.
d Data were missing for 4509 outcomes.
e Data were missing for 4630 outcomes. All models adjusted for mother's age at delivery, plurality, race, study region, and smoking status.
Abbreviation: PROM, premature rupture of the membrane. a The reference category is "No influenza."
Of the 617 women with A(H1N1)pdm09 infection to whom antivirals were dispensed, 553 received early treatment (ie, within 2 days of diagnosis), while 34 received late treatment (ie, 3-7 days after diagnosis). Mothers receiving late treatment were >3 times as likely to be hospitalized within 30 days, compared with those who received early antiviral therapy (crude OR, 3.43 [95% CI, 1.55-7.56]).
DISCUSSION
In this population-based study of >100 000 mother-infant pairs, we found that mothers with a diagnosis of A(H1N1) pdm09 infection were more than twice as likely to be hospitalized as mothers with a diagnosis of seasonal influenza virus infection. These findings are consistent with those from other studies [3, 4] . Although some of this increase might have been due to the high visibility and concern about the potential risk for adverse effects of A(H1N1)pdm09 infection on pregnancy, there was a large increase in the risk of hospitalization associated with A(H1N1)pdm09 infection, even after excluding women whose brief hospitalization (<24 hours) may have been for observational purposes only.
We also found that early antiviral therapy was associated with a substantially reduced risk-by almost two-thirds-for hospitalization. Other research has shown that early treatment with oseltamivir among patients hospitalized with A(H1N1)pdm09 infection reduced the risk of further complications [14] [15] [16] and death [4, 17] ; ours is the first study to show the importance and impact of early therapy among pregnant women.
The size of our cohort allowed us to explore the impact of A(H1N1)pdm09 infection on women with specific comorbidities, including asthma. Diagnosis of A(H1N1)pdm09 infection during pregnancy was associated with LBW among infants delivered by women with asthma. It is possible that infection further exacerbated respiratory insufficiency in pregnant women with asthma, resulting in restricted fetal weight gain during pregnancy.
We also found that seasonal influenza virus infection during pregnancy was associated with a significant increase in the risk for delivery of SGA infants (OR, 1.59 [95% CI, 1.15-2.20), whereas A(H1N1)pdm09 infection was not (OR, 0.99), highlighting the fact that seasonal influenza virus also poses a risk to the developing infant [18] . Only 3% of pregnant women with seasonal influenza virus infection received an antiviral, compared with 64% of pregnant women with H1N1pdm09 infection, so some of the attenuated impact of H1N1pdm09 during pregnancy might have resulted from the much greater use of antiviral therapy during the pandemic.
In our study, women with a diagnosis of H1N1pdm09 infection were more likely to be younger and to be black, similar to others' findings [3, 4, 12] . The higher rates of obesity, asthma, and neurological disease among mothers with a diagnosis of A(H1N1)pdm09 infection are also consistent with findings from several published case series [4, 10, 12, 18] . We found that mothers with A(H1N1)pdm09 infection had a higher risk of antepartum hemorrhage and other complications, compared with noninfected mothers, and a higher rate of fetal abnormalities. The relatively high rate of some of these outcomes may be due to the higher prevalence of A(H1N1) pdm09 infection in the third trimester, when infection would be most likely to affect labor and delivery. In contrast, seasonal influenza virus infection was most prevalent during the first trimester, when it would be less likely to have an effect on labor and delivery. Our study had a number of strengths. The cohort was large, diverse, and derived from a clearly defined population. Because we were able to follow mothers and infants longitudinally, we were able to examine a wide range of maternal and neonatal outcomes and to perform subanalyses by underlying conditions. Finally, while most prior studies reporting on the effects of A(H1N1) pdm09 infection in pregnant women focused on hospitalized cases, our population-based approach enabled us to investigate the impact of diagnoses of A(H1N1)pdm09 infection and seasonal influenza virus infection in the ambulatory setting, as well.
This study also had several limitations. Because we determined the periods of seasonal influenza virus and A(H1N1) pdm09 circulation on the basis of surveillance data for broad geographic census regions, there is the potential for misclassification of diagnoses. Our study did not assess deaths, as death certificate data were not yet available from all of the states. Finally, our methods of identifying influenza virus infection, which depended on administrative records, almost certainly missed some cases of medically attended influenza and may have misclassified some patients who did not actually have influenza. Given the attention surrounding A(H1N1) pdm09, there may have been differential ascertainment of influenza during our study period, leading us to likely underestimate the magnitude of the association between A(H1N1) pdm09 infection and the outcomes seen here.
In summary, we found a strong protective effect against hospitalization associated with early antiviral treatment of pregnant women with A(H1N1)pdm09 infection. Although we found associations between A(H1N1)pdm09 infection and seasonal influenza virus infection diagnoses and a number of adverse outcomes, we did not find important differences in the pregnancy outcomes between mothers with a diagnosis of seasonal influenza virus infection and those with a diagnosis of A (H1N1)pdm09 infection. This large, population-based study of A(H1N1)pdm09 infection diagnosis among pregnant women adds to the evidence demonstrating the need for early diagnosis and treatment of influenza among infected pregnant women, to prevent potentially serious maternal and infant outcomes.
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